a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders
Industry Biotechnology
A.I.dvisor tells us that AIM and SLN have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AIM and SLN's prices will move in lockstep.
Ticker / NAME | Correlation To AIM | 1D Price Change % | ||
---|---|---|---|---|
AIM | 100% | +0.24% | ||
SLN - AIM | 28% Poorly correlated | -3.41% | ||
ELVN - AIM | 27% Poorly correlated | +3.48% | ||
PIRS - AIM | 24% Poorly correlated | N/A | ||
ENTBF - AIM | 23% Poorly correlated | -2.20% | ||
MNPR - AIM | 23% Poorly correlated | +14.91% | ||
More |